Research programme: PSMAxCD3 bispecific T-cell engagers - AbCellera
Latest Information Update: 04 Dec 2023
At a glance
- Originator Abcellera
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 03 Nov 2023 PSMA/CD3 bispecific T-cell engagers is available for licensing as of 03 Nov 2023. https://abcellera.com/partnership/ (AbCellera website, November 2023)
- 03 Nov 2023 Early research in Cancer in Canada (Parenteral) prior to November 2023
- 20 Mar 2023 AbCellera files a PCT patent application with WIPO for Anti-CD3 antibodies and t-cell engager worldwide